Silence Therapeutics jumps after mid-stage trial data for blood cancer drug

Protagonist Therapeutics

10/08/2026 17:23

** U.S.-listed shares of Silence Therapeutics SLNCF.PK, SLN.O rise 35% to over 20-month high of $16.17
** Co says its experimental drug, divesiran, met its main goal of a mid-stage trial in treating patients with polycythemia vera, a rare blood cancer
** The response rate is 88% in patients treated with divesiran, compared with 19% for placebo
** Cantor analyst Prakhar Agrawal called the data "excellent," noting divesiran "meaningfully exceeded the efficacy" of Takeda 4502.T and Protagonist's PTGX.O rival drug, rusfertide
** The drug significantly reduced the need for blood-removal procedures, phlebotomies, and helped keep patients' blood thickness under control, co says
** Co plans to start a late-stage trial in the first half of 2027
** Including session's move, stock more than doubled YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))